Chlorpromazine

Global Animal Sedative Market (2021 to 2026) - Growth, Trends, COVID-19 Impact and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Monday, September 27, 2021
Veterinary, Health, Adoption, CNS, Lists of countries and territories, Animal, Thioridazine, Chlorpromazine, Zoonosis, Acepromazine, Canine influenza, Growth, Trifluoperazine, Awareness, Medicine, Dopamine, Research, Allergy, Rabies, Antiemetic, Agitation, Veterinary medicine, Phenothiazine, Government, Pharmaceutical industry

They are employed as tranquilizers, preanesthetic drugs, antiemetics, and for the treatment of CNS agitation in domestic animals.

Key Points: 
  • They are employed as tranquilizers, preanesthetic drugs, antiemetics, and for the treatment of CNS agitation in domestic animals.
  • The animals are provided sedative drugs for their cure from zoonoses, phenothiazines being the parent ingredient for the most regularly used sedative drugs.
  • Hence, the increase in the demand of this segment will drive the overall animal sedative market.
  • This, together with the rising frequency of animal diseases, will help this region maintain its market dominance in the years ahead.

Lannett Begins Marketing Chlorpromazine Hydrochloride Tablets

Retrieved on: 
Monday, February 8, 2021
Branches of biology, Drugs, Chloroarenes, Typical antipsychotics, Biology, Antiemetics, Chlorpromazine, Phenothiazines, RTT, Magnesium in biology, Somnogen Canada Inc

PHILADELPHIA, Feb. 8, 2021 /PRNewswire/ --Lannett Company, Inc. (NYSE: LCI) today announced that it has begun marketing Chlorpromazine Hydrochloride Tablets, USP, 10 mg, 25 mg, 50 mg, 100 mg and 200 mg.

Key Points: 
  • PHILADELPHIA, Feb. 8, 2021 /PRNewswire/ --Lannett Company, Inc. (NYSE: LCI) today announced that it has begun marketing Chlorpromazine Hydrochloride Tablets, USP, 10 mg, 25 mg, 50 mg, 100 mg and 200 mg.
  • "Chlorpromazine Hydrochloride Tablets, an internally developed product,is used to treat psychotic disorders such as schizophrenia or manic-depression in adults," said Tim Crew, chief executive officer of Lannett.
  • "We expect Chlorpromazine Hydrochloride Tablets will be a solid addition to our product offering, with margins above our company average."
  • Chlorpromazine Hydrochloride Tablets, USP, 10 mg, 25 mg, 50 mg, 100 mg and 200 mg is the therapeutic equivalent of the reference listed drug Thorazine Tablets10 mg, 25 mg, 50 mg, 100 mg and 200 mg of GlaxoSmithKline.

Frontier Pharma: Schizophrenia - Diverse First-in-Class Pipeline Shows Promise for Treatment of Negative and Cognitive Symptoms

Retrieved on: 
Tuesday, December 4, 2018
Psychiatry, Schizophrenia, Neuroscience, Abnormal psychology, Psychopathology, RTT, Chloroarenes, Psychosis, Antipsychotic, Management of schizophrenia, Chlorpromazine, Childhood schizophrenia

NEW YORK, Dec. 3, 2018 /PRNewswire/ -- Frontier Pharma: Schizophrenia - Diverse First-in-Class Pipeline Shows Promise for Treatment of Negative and Cognitive Symptoms

Key Points: 
  • NEW YORK, Dec. 3, 2018 /PRNewswire/ -- Frontier Pharma: Schizophrenia - Diverse First-in-Class Pipeline Shows Promise for Treatment of Negative and Cognitive Symptoms
    Schizophrenia is a severe chronic mental disorder affecting a person's mental, emotional and physical wellbeing.
  • In the 1960s, the antipsychotic drug Chlorpromazine entered the market for the treatment of schizophrenia, spurring the development of first-generation or 'typical' antipsychotics.
  • The schizophrenia pipeline is relatively small, given the large patient population and well-defined unmet needs, with a total of 160 products in active development.
  • From the research finding included in the report "Frontier Pharma: Schizophrenia - Diverse First-in-Class Pipeline Shows Promise for Treatment of Negative and Cognitive Symptoms"; First-in-class products have the greatest potential in terms of development and commercial prospects.

Amneal Announces FDA Approval and Launch of Generic Chlorpromazine Hydrochloride Tablets USP and Approval of Methylergonovine Maleate Tablets USP

Retrieved on: 
Wednesday, September 12, 2018
Neurochemistry, Pharmacology, Chemistry, RTT, Hepatotoxins, Analgesics, Chloroarenes, Antipyretics, Chlorpromazine, Methylergometrine, Tablet computer, Ketamine

According to IQVIA, the U.S. market for chlorpromazine hydrochloride tablets USP is estimated to be approximately $207 million in annual sales for the 12 months ended July 2018.

Key Points: 
  • According to IQVIA, the U.S. market for chlorpromazine hydrochloride tablets USP is estimated to be approximately $207 million in annual sales for the 12 months ended July 2018.
  • "The immediate launch of Chlorpromazine Hydrochloride Tablets, a potentially high-value opportunity, further enhances our generic portfolio and our commitment to provide patients with a more affordable treatment option."
  • The Company also received approval for a generic version of Methergine Tablets USP, 0.2 mg (Methylergonovine Maleate Tablets USP, 0.2 mg ), which it expects to launch shortly.
  • According to IQVIA, methylergonovine maleate tablets had annual U.S. sales of approximately $73 million for the 12 months ending July 2018.